Stockscreener 앱 받기
2.29
10.10%
0.21
시간 외 거래:
2.29
전일 마감가:
$2.08
열려 있는:
$2.2
하루 거래량:
19,920
Relative Volume:
1.20
시가총액:
$26.88M
수익:
-
순이익/손실:
-
주가수익비율:
-6.5786
EPS:
-0.3481
순현금흐름:
-
1주 성능:
-0.43%
1개월 성능:
+2.23%
6개월 성능:
+50.66%
1년 성능:
-28.44%
1일 변동 폭
$2.20
$2.3305
1주일 범위
$1.77
$2.40
52주 변동 폭
$1.0775
$4.40
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
명칭
Akari Therapeutics Plc Adr
전화
(646) 350-0702
주소
22 BOSTON WHARF ROAD, BOSTON
AKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| AKTX | 2.29 | 26.88M | 0 | 0 | 0 | -0.3481 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-01-04 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | 업그레이드 | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | 재확인 | Chardan Capital Markets | Sell |
| 2016-07-11 | 개시 | Chardan Capital Markets | Sell |
모두보기
Akari Therapeutics Plc Adr 주식(AKTX)의 최신 뉴스
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Benzinga
Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments | AKTX Stock News - StockTitan
Akari Therapeutics shareholders approve Peak Bio merger - Investing.com
Akari Therapeutics shareholders approve Peak Bio merger By Investing.com - Investing.com UK
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - StockTitan
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger - StockTitan
Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India
Akari Therapeutics PlcADR (AKTX) Price Target Increased by 45.45% to 81.60 - MSN
Akari Therapeutics appoints Rob Bazemore to board - Investing.com
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - StockTitan
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy - StockTitan
Akari Therapeutics shareholders approve board and auditors - Investing.com India
Akari Therapeutics shareholders approve board and auditors By Investing.com - Investing.com India
Zoomcar announces departure of President Adarsh Menon By Investing.com - Investing.com
Phillips Edison expands board, appoints Devin Murphy By Investing.com - Investing.com India
Goldman Sachs raises Birkenstock target to $59.50, keeps neutral stance By Investing.com - Investing.com
Shopify’s market position 'promising for growth', Evercore ISI sees stock upside - Investing.com
Akari Therapeutics secures $7.6 million in private financing By Investing.com - Investing.com
Closing Figures Unveiled: Akari Therapeutics Plc ADR (AKTX) Drop -4.19, Closes at 1.72 – DWinneX - The Dwinnex
Arbe Robotics sees high demand for convertible debt By Investing.com - Investing.com
Insmed executive sells over $270k in company stock By Investing.com - Investing.com
Dialing Up Nights Out: Heineken® & Bodega Launch the No-Frills 'Boring Phone' | GlobeNewswire by notified - NTB Kommunikasjon
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer I - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 T - Benzinga
48 Stocks Moving In Friday's Mid-Day SessionAfya (NASDAQ:AFYA) - Benzinga
GCI: Best & Worst Performing Small Cap Stocks for July 19, 2019 - StockNews.com
52 Biggest Movers From YesterdayAyala Pharmaceuticals (OTC:ADXS), Altisource Asset Mgmt (AMEX:AAMC) - Benzinga
'Flying Whale' Blimp That Never Lands Joins Global Airship Race - Bloomberg
CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% - Investing.com
22 Stocks Moving In Monday's Pre-Market SessionAkari Therapeutics (NASDAQ:AKTX), argenx (NASDAQ:ARGX) - Benzinga
Mid-Morning Market Update: Markets Fall; Initial Jobless Claims Drop to 259,000Akari Therapeutics (NAS - Benzinga
Dow Jones News: Dow Rallies 200 Points After Macron and Le Pen Win First Round of French Election - Money Morning
25 Stocks Moving In Tuesday's Pre-Market SessionAkari Therapeutics (NASDAQ:AKTX), Aurinia Pharmaceutic - Benzinga
Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher - Nasdaq
Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat
Lockheed Lands Airship Deal as Oil Industry Spurs Blimp Revival - Bloomberg
Two Stocks That Have Deerfield Management And Anchor Bolt Capital Excited - Insider Monkey
Akari Therapeutics Plc Adr (AKTX) 재무 분석
Akari Therapeutics Plc Adr (AKTX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):